Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Montelukast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 known ✓ | Q9Y271 | 6/20 | 1.00 |
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | FPR1 | P21462 | 1/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.87 |
| ▸ | RECQL | P46063 | 1/20 | 0.87 |
| ▸ | BLM | P54132 | 1/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.87 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.87 |
| ▸ | EGFR | P00533 | 1/20 | 0.87 |
| ▸ | ESR1 | P03372 | 1/20 | 0.87 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.87 |
| ▸ | FYN | P06241 | 1/20 | 0.87 |
| ▸ | PGR | P06401 | 1/20 | 0.87 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.87 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.87 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.87 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Montelukast SCHEMBL31425566 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL9414 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL9415 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL29840730 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL29573125 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL3229836 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL29369947 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL4788140 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL8533560 | 0.99 | CYSLTR1 (0.99) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL6381434 | 0.99 | CYSLTR1 (0.99) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007088545-A2 | NOVEL PROCESS FOR PREPARING 1-(MERCAPTOMETHYL) CYCLOPROPANEACETIC ACID, A USEFUL INTERMEDIATE IN THE PREPARATION OF MONTELUKAST AND SALTS THEREOF | CHEMAGIS LTD. (IL) | 2007-08-09 | — | — | WO | disclosed |
| EP-1760077-A1 | Montelukast free acid polymorphs | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-03-07 | — | — | EP | disclosed |
| US-7156089-B2 | Method and device for treatment of respiratory tract disorders | PHARMACEUTICAL DESIGN, LLC | 2007-01-02 | — | — | US | disclosed |
| EP-1711166-A1 | STABLE AMORPHOUS FORMS OF MONTELUKAST SODIUM | CHEMAGIS LTD. (IL) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005074893-A1 | STABLE AMORPHOUS FORMS OF MONTELUKAST SODIUM | CHEMAGIS LTD. (IL) | 2005-08-18 | — | — | WO | disclosed |
| US-20030234198-A1 | Method and device for treatment of respiratory tract disorders | PHARMACEUTICAL DESIGN, LLC | 2003-12-25 | — | — | US | disclosed |